Savara (SVRA) Return on Capital Employed (2011 - 2026)
Savara's (SVRA) quarterly Return on Capital Employed came in at 60.41% in Q1 2026, down 271.0% year-on-year from 35.33% in Q1 2025, and up 13.57% on a QoQ basis from 69.89% in Q4 2025.
Savara (SVRA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Savara (SVRA) has 16 years of Return on Capital Employed data on file, last reported at 60.41% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 271.0% year-over-year to 60.41% in Q1 2026; TTM through Mar 2026 was 60.41%, a 271.0% decrease from a year earlier, with the FY2025 full-year figure at 58.07%, down 90.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 60.41%, up from 69.89% in the prior quarter.
- Over the last five years, Return on Capital Employed for SVRA reached as high as 24.11% in Q2 2022 and fell as low as 89.47% in Q3 2025.
- Historically, Return on Capital Employed has averaged 47.12% across 5 years, with a median of 44.5% in 2024.
- Across the five-year window, Return on Capital Employed surged 467 bps in 2022 and sank 3866 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 28.16% in 2022, then slipped by 26 bps to 35.46% in 2023, then plunged by 38 bps to 48.88% in 2024, then tumbled by 43 bps to 69.89% in 2025, then climbed by 14 bps to 60.41% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 60.41% in Q1 2026, 69.89% in Q4 2025, and 89.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | -60.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.41% |
| Dec 31, 2025 | -69.89% |
| Sep 30, 2025 | -89.47% |
| Jun 30, 2025 | -72.07% |
| Mar 31, 2025 | -57.69% |
| Dec 31, 2024 | -48.88% |
| Sep 30, 2024 | -50.81% |
| Jun 30, 2024 | -59.07% |
| Mar 31, 2024 | -44.50% |
| Dec 31, 2023 | -35.46% |
| Sep 30, 2023 | -37.50% |
| Jun 30, 2023 | -38.53% |
| Mar 31, 2023 | -33.09% |
| Dec 31, 2022 | -28.16% |
| Sep 30, 2022 | -26.24% |
| Jun 30, 2022 | -24.11% |
| Mar 31, 2022 | -25.22% |
| Dec 31, 2021 | -24.80% |
| Sep 30, 2021 | -24.20% |
| Jun 30, 2021 | -22.74% |